Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-monthly de novo darbepoetin alfa for anemia correction in non-dialysis chronic kidney disease
2006-003173-27Phase 3Completed
- Sponsor
- Amgen
- Start
- Sep 2006
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of darbepoetin alfa in anemia of renal disease, sponsored by Amgen. Primary endpoint: Primary efficacy endpoint. Started Sep 2006; status: completed.
02
Drugs
darbepoetin alfa
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on 2006-003173-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003173-27.